Stock info Molecular Partners | Filter  Basic-Info

Molecular Partners

The global health care companies gained around 102 percent over the period 2006-2016. Measured since 2011 the sector is 64 percent higher and over the past 12 months (December 2015-2016) there is a plus of 102 percent.

The past year was a profitable year for the Molecular Partners investors

The period between December 2015 and December 2016 was a loss-making period for the investors in Molecular Partners. The stock lost around 45 percent. The period between August 2011 and August 2016 was a bad period for the investors. The stock lost around 0 percent.

The Swiss company didn't pay out any dividends (in the past 5 years).

At the end of 2015 the company had around 843 people employed.

Healthy financed: not so much debt Molecular Partners

At the end of 2015 the Swiss company had a balance sheet of 219,4 million CHFF. The total debt of the health care company was at the end of 2015 67,61 million CHFF, which equals around 30,82 percent of the total balance sheet. As per the end of 2015 Molecular Partners's price/earnings-ratio equaled -2510. So investors paid for 1 stock -2510 times the earnings per share of 2015. We could say that based on it's price/earnings-ratio and dividend yield the Swiss stock can be seen as a growth stock.

At the end of 2015 the health care company's market size (her number of outstanding share times the stock price) equaled around 697,57 million CHFF. At the end of 2015 around 19,54 million stocks were listed.

All Molecular Partners's financial reports are located here. More information about Molecular Partners can be found it's website. .